Clinical Trial Update: Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating autologous mesenchymal stem cells as a regenerative treatment for multiple sclerosis, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• Mesenchymal Autologous Stem Cells

Snippet

Sponsor: Haukeland University Hospital | Conditions: Multiple Sclerosis, Progressive Multiple Sclerosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING